Oxidative stress/reactive metabolite gene expression signature in rat liver detects idiosyncratic hepatotoxicants

Toxicology and Applied Pharmacology

Volumn 275, Issue 3, 2014, Pages 189-197

  Leone, Angelique ^a   Nie, Alex ^a   Brandon Parker, J ^a   Sawant, Sharmilee ^a   Piechta, Leigh Anne ^a   Kelley, Michael F ^a   Mark Kao, L ^a   Jim Proctor, S ^a   Verheyen, Geert ^a   Johnson, Mark D ^a   Lord, Peter G ^a   McMillian, Michael K ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Adverse drug reactions; DILI; Drug induced liver injury; Idiosyncratic hepatotoxicity; Oxidative stress; Reactive metabolites

Indexed keywords

AMINOGLUTETHIMIDE; AMITRIPTYLINE; CARBAMAZEPINE; CHLORAMPHENICOL; CHLORPROMAZINE; CLOZAPINE; CORTICOTROPIN; COUMARIN; CYPROTERONE ACETATE; DANTROLENE; DIPYRIDAMOLE; DISULFIRAM; ENALAPRIL; ETHINYLESTRADIOL; FELBAMATE; FLUTAMIDE; GLIBENCLAMIDE; ISONIAZID; METHAPYRILENE; NALTREXONE; NIFEDIPINE; NIMESULIDE; PHENACETIN; PHENOBARBITAL; RITONAVIR; SULFAMETHOXAZOLE; SULINDAC; TAMOXIFEN; TOXIC SUBSTANCE; VALPROIC ACID;

ANIMAL TISSUE; ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; BONE MARROW SUPPRESSION; CONTROLLED STUDY; GENE EXPRESSION; IDIOSYNCRATIC HEPATOTOXICITY; LIVER TOXICITY; MACROPHAGE ACTIVATION; MALE; METABOLITE; MICROARRAY ANALYSIS; NONHUMAN; OXIDATIVE STRESS; RAT; RNA ISOLATION; SENSITIVITY AND SPECIFICITY;

RATTUS;

ADVERSE DRUG REACTIONS; DILI; DRUG INDUCED LIVER INJURY; IDIOSYNCRATIC HEPATOTOXICITY; OXIDATIVE STRESS; REACTIVE METABOLITES;

ANIMALS; DATABASES, GENETIC; DRUG-INDUCED LIVER INJURY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC MARKERS; LIVER; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; TOXICOGENETICS;

EID: 84896729498     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2014.01.017     Document Type: Article

References (42)

1. Andrès E., Maloisel F. Idiosyncratic drug-induced agranulocytosis or acute neutropenia. Curr. Opin. Hematol. 2008, 15:15-21. 10.1097/MOH.1090b1013e3282f1015fb1099.
2. Bharadwaj M., Illing P., Theodossis A., Purcell A.W., Rossjohn J., McCluskey J. Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. Annu. Rev. Pharmacol. Toxicol. 2012, 52:401-431.
3. Chalasani N., Fontana R.J., Bonkovsky H.L., Watkins P.B., Davern T., Serrano J., Yang H., Rochon J. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008, 135:1924-1934. (e1924).
4. Chitturi S., George J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Seminars in liver disease 2002, 169-184. Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.:+ 1 (212) 584-4662, (Copyright© 2002 by).
5. De Vriese A.S., Van Coster R., Smet J., Seneca S., Lovering A., Van Haute L.L., Vanopdenbosch L.J., Martin J.-J., Ceuterick-de Groote C., Vandecasteele S., Boelaert J.R. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin. Infect. Dis. 2006, 42:1111-1117.
6. Evans D.C., Lyubimov A.V. Covalent Drug-Protein Adducts: An Exploration of Their Role in Drug-Induced Liver and General Organ Toxicity, Encyclopedia of Drug Metabolism and Interactions 2011, John Wiley & Sons, Inc.
7. Evans D.C., Watt A.P., Nicoll-Griffith D.A., Baillie T.A. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 2004, 17:3-16.
8. Foster J.R., Jacobsen M., Kenna G., Schulz-Utermoehl T., Morikawa Y., Salmu J., Wilson I.D. Differential effect of troglitazone on the human bile acid transporters, MRP2 and BSEP, in the PXB hepatic chimeric mouse. Toxicol. Pathol. 2012, 40:1106-1116.
9. Fuller R.K., Gordis E. Does disulfiram have a role in alcoholism treatment today?. Addiction 2004, 99:21-24.
10. García-Cortés M., Lucena M.I., Andrade P.J., Camargo R., Alcántara R. Is the Naranjo probability scale accurate enough to ascertain causality in drug-induced hepatotoxicity?. Ann. Pharmacother. 2004, 38:1540-1541.
11. Gill H.J., Hough S.J., Naisbitt D.J., Maggs J.L., Kitteringham N.R., Pirmohamed M., Park B.K. The relationship between the disposition and immunogenicity of sulfamethoxazole in the rat. J. Pharmacol. Exp. Ther. 1997, 282:795-801.
12. Gracon S.I., Knapp M.J., Berghoff W.G., Pierce M., DeJong R., Lobbestael S.J., Symons J., Dombey S.L., Luscombe F.A., Kraemer D. Safety of tacrine: clinical trials, treatment IND, and postmarketing experience. Alzheimer Dis. Assoc. Disord. 1998, 12:93-101.
13. Guengerich F.P. Mechanisms of drug toxicity and relevance to pharmaceutical development. Drug Metab. Pharmacokinet. 2011, 26:3-14.
14. Hagley M., Benak R., Hulisz D. Suspected cross-reactivity of enalapril- and captopril-induced hepatotoxicity. Ann. Pharmacother. 1992, 26:780-781.
15. Hill A., Mesens N., Steemans M., Xu J.J., Aleo M.D. Comparisons between in vitro whole cell imaging and in vivo zebrafish-based approaches for identifying potential human hepatotoxicants earlier in pharmaceutical development. Drug Metab. Rev. 2012, 44:127-140.
16. Iuliano L., Pedersen J.Z., Rotilio G., Ferro D., Violi F. A potent chain-breaking antioxidant activity of the cardiovascular drug dipyridamole. Free Radic. Biol. Med. 1995, 18:239-247.
17. Kang P., Dalvie D., Smith E., Zhou S., Deese A., Nieman J.A. Bioactivation of flutamide metabolites by human liver microsomes. Drug Metab. Dispos. 2008, 36:1425-1437.
18. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. 2005, 4:489-499.
19. Kohen R., Nyska A. Invited review: oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. Toxicol. Pathol. 2002, 30:620-650.
20. Lee J.H., Khor T.O., Shu L., Su Z.-Y., Fuentes F., Kong A.-N.T. Dietary phytochemicals and cancer prevention: nrf2 signaling, epigenetics, and cell death mechanisms in blocking cancer initiation and progression. Pharmacol. Ther. 2013, 137:153-171.
21. Leone A.M., Kao L.M., McMillian M.K., Nie A.Y., Parker J.B., Kelley M.F., Usuki E., Parkinson A., Lord P.G., Johnson M.D. Evaluation of felbamate and other antiepileptic drug toxicity potential based on hepatic protein covalent binding and gene expression. Chem. Res. Toxicol. 2007, 20:600-608.
22. Li A.P. Accurate prediction of human drug toxicity: a major challenge in drug development. Chem. Biol. Interact. 2004, 150:3-7.
23. Luyendyk J.P., Maddox J.F., Cosma G.N., Ganey P.E., Cockerell G.L., Roth R.A. Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. J. Pharmacol. Exp. Ther. 2003, 307:9-16.
24. McMillian M., Nie A.Y., Parker J.B., Leone A., Bryant S., Kemmerer M., Herlich J., Liu Y., Yieh L., Bittner A., Liu X., Wan J., Johnson M.D. A gene expression signature for oxidant stress/reactive metabolites in rat liver. Biochem. Pharmacol. 2004, 68:2249-2261.
25. McMillian M., Nie A.Y., Parker J.B., Leone A., Kemmerer M., Bryant S., Herlich J., Yieh L., Bittner A., Liu X., Wan J., Johnson M.D. Inverse gene expression patterns for macrophage activating hepatotoxicants and peroxisome proliferators in rat liver. Biochem. Pharmacol. 2004, 67:2141-2165.
26. McMillian M., Nie A., Parker J.B., Leone A., Kemmerer M., Bryant S., Herlich J., Yieh L., Bittner A., Liu X., Wan J., Johnson M.D., Lord P. Drug-induced oxidative stress in rat liver from a toxicogenomics perspective. Toxicol. Appl. Pharmacol. 2005, 207:171-178.
27. Metushi I.G., Nakagawa T., Uetrecht J. Direct oxidation and covalent binding of isoniazid to rodent liver and human hepatic microsomes: humans are more like mice than rats. Chem. Res. Toxicol. 2012, 25:2567-2576.
28. Miquel M., Soler A., Vaqué A., Ojanguren I., Costa J., Planas R. Suspected cross-hepatotoxicity of flutamide and cyproterone acetate. Liver Int. 2007, 27:1144-1147.
29. Nakayama S., Atsumi R., Takakusa H., Kobayashi Y., Kurihara A., Nagai Y., Nakai D., Okazaki O. A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding. Drug Metab. Dispos. 2009, 37:1970-1977.
30. Navarro V.J., Senior J.R. Drug-related hepatotoxicity. N. Engl. J. Med. 2006, 354:731-739.
31. Nie A.Y., McMillian M., Brandon Parker J., Leone A., Bryant S., Yieh L., Bittner A., Nelson J., Carmen A., Wan J. Predictive toxicogenomics approaches reveal underlying molecular mechanisms of nongenotoxic carcinogenicity. Mol. Carcinog. 2006, 45:914-933.
32. Obach R.S., Kalgutkar A.S., Soglia J.R., Zhao S.X. Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Chem. Res. Toxicol. 2008, 21:1814-1822.
33. Olson H., Betton G., Robinson D., Thomas K., Monro A., Kolaja G., Lilly P., Sanders J., Sipes G., Bracken W., Dorato M., Van Deun K., Smith P., Berger B., Heller A. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 2000, 32:56-67.
34. Reuben A., Koch D.G., Lee W.M. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010, 52:2065-2076.
35. Shen C., Meng Q., Zhang G. Species-specific toxicity of troglitazone on rats and human by gel entrapped hepatocytes. Toxicol. Appl. Pharmacol. 2012, 258:19-25.
36. Srivastava A., Maggs J.L., Antoine D.J., Williams D.P., Smith D.A., Park B.K. Role of reactive metabolites in drug-induced hepatotoxicity. Adverse Drug Reactions 2010, 165-194. Springer, Berlin Heidelberg. J. Uetrecht (Ed.).
37. Stepan A.F., Walker D.P., Bauman J., Price D.A., Baillie T.A., Kalgutkar A.S., Aleo M.D. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem. Res. Toxicol. 2011, 24:1345-1410.
38. Sulkowski M.S. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin. Infect. Dis. 2004, 38:S90-S97.
39. Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu. Rev. Pharmacol. Toxicol. 2007, 47:513-539.
40. Walgren J.L., Mitchell M.D., Thompson D.C. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit. Rev. Toxicol. 2005, 35:325-361.
41. Wen B., Ma L., Zhu M. Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem. Biol. Interact. 2008, 173:59-67.
42. Zhou S., Chan E., Duan W., Huang M., Chen Y.-Z. Drug bioactivation covalent binding to target proteins and toxicity relevance. Drug Metab. Rev. 2005, 37:41-213.